Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype

[1] Fitzmaurice C(2018)Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 To 2016: A systematic analysis for the global burden of disease study JAMA Oncol 4 1553-1568

[2] Akinyemiju TF(2015)Intratumor heterogeneity in hepatocellular carcinoma Clin Cancer Res 21 1951-1961

[3] Al Lami FH(2009)EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features Gastroenterology 136 1012-1024

[4] Alam T(2014)Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma Histopathology 64 935-950

[5] Alizadeh-Navaei R(2015)Cancer stem cells in oesophageal squamous cell carcinoma: Identification, prognostic and treatment perspectives Crit Rev Oncol Hematol 96 9-19

[6] Allen C(2014)EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205 Br J Cancer 111 955-964

[7] Alsharif U(2013)High EpCAM expression is linked to proliferation and lauren classification in gastric cancer BMC Res Notes 6 253-1134

[8] Alvis-Guzman N(2013)Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer Cancer Sci 104 1127-582

[9] Amini E(2012)EpCAM expression is an indicator of recurrence in basal-like breast cancer Breast Cancer Res Treat 133 575-1497

[10] Friemel J(2013)Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma Hepatology 57 1484-1461

[1] Fitzmaurice C(2018)Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 To 2016: A systematic analysis for the global burden of disease study JAMA Oncol 4 1553-1568

[2] Akinyemiju TF(2015)Intratumor heterogeneity in hepatocellular carcinoma Clin Cancer Res 21 1951-1961

[3] Al Lami FH(2009)EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features Gastroenterology 136 1012-1024

[4] Alam T(2014)Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma Histopathology 64 935-950

[5] Alizadeh-Navaei R(2015)Cancer stem cells in oesophageal squamous cell carcinoma: Identification, prognostic and treatment perspectives Crit Rev Oncol Hematol 96 9-19

[6] Allen C(2014)EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205 Br J Cancer 111 955-964

[7] Alsharif U(2013)High EpCAM expression is linked to proliferation and lauren classification in gastric cancer BMC Res Notes 6 253-1134

[8] Alvis-Guzman N(2013)Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer Cancer Sci 104 1127-582

[9] Amini E(2012)EpCAM expression is an indicator of recurrence in basal-like breast cancer Breast Cancer Res Treat 133 575-1497

[10] Friemel J(2013)Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma Hepatology 57 1484-1461